Form 4: Achieve Life Sciences Executive Acquires Performance-Based Stock Units

Cindy Jacobs, President & CMO of Achieve Life Sciences, was granted 130,000 Performance Restricted Stock Units (PRSUs) on January 28, 2025, according to a Form 4 filing.

Summary

• Cindy Jacobs, the President & CMO of Achieve Life Sciences, received 130,000 Performance Restricted Stock Units (PRSUs) on January 28, 2025.
• Each PRSU represents a contingent right to receive one share of Achieve Life Sciences' common stock upon settlement.
• The number of shares that will ultimately vest can range from 0% to 100% of the initially granted PRSUs, depending on the achievement of certain milestones during the measurement period.
• The PRSUs were directly owned by Cindy Jacobs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation. The performance-based nature of the award is a slight positive, aligning executive interests with company goals.

Positives

• The granting of PRSUs aligns the executive's interests with the company's performance, incentivizing the achievement of key milestones.

Risks

• The actual number of shares that will vest from the PRSUs is uncertain and depends on the achievement of performance milestones.

Future Outlook

The vesting of the PRSUs is contingent upon the achievement of certain milestones during the measurement period, which will determine the actual number of shares ultimately received.

Industry Context

This type of equity compensation is common in the biotech industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Performance-based equity awards are a standard practice in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar performance-based stock units to incentivize their executives to achieve specific clinical, regulatory, or financial goals.
• The vesting criteria for these awards typically involve milestones related to drug development, regulatory approvals, or revenue targets.

Stakeholder Impact

• Shareholders may view the performance-based equity award as a positive incentive for management to achieve company goals.
• Employees may see this as a sign of confidence in the company's future prospects.

Next Steps

• The company will monitor the achievement of the performance milestones associated with the PRSUs.
• The vesting of the PRSUs will be determined based on the achievement of these milestones.

Key Dates